Axial Biotherapeutics Presents Preclinical Data on Microbiome-Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Dr. Torsten Madsen, acting Chief Medical Officer will be presenting preclinical data highlighting the strong association between bacteria-derived metabolites and autism spectrum disorder (ASD) at the Society for Neuroscience 2019 Annual Meeting on Saturday, October 19, 2019 in Chicago, IL.

“We are pleased to share these preclinical data, which further validate our scientific rationale and approach to treat ASD. Understanding the association between sustained levels of metabolites in systemic circulation and core and non-core behavioral symptoms associated with ASD is an important advance,” said David Donabedian, Ph.D., and Co-founder and Chief Executive Officer of Axial Biotherapeutics. “Based on these data, we believe that our approach, i.e., that modulation of bacteria-derived metabolites may represent an important new treatment paradigm for the core and non-core symptoms of ASD.”

Axial Biotherapeutics is currently investigating AB-2004, a first-in-class, therapeutic that removes metabolites in the gastrointestinal (GI) tract, in a Phase 1/2a safety and tolerability study.

Presentation Details:

Presentation Title: “Microbiome derived metabolites associated with autism spectrum disorder negatively impact multiple aspects of neuronal development and functionality”
Presenter: Torsten Madsen, MD, PhD
Poster Presentation: #030.08, Saturday, October 18, 2019, 1:00 PM CT

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191018005320/en/

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
[email protected]